NASDAQ:CKPT Checkpoint Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.05 +0.01 (+0.96%) (As of 07/5/2022 02:33 PM ET) Add Compare Share Today's Range$1.04▼$1.0650-Day Range$0.97▼$1.4552-Week Range$0.96▼$4.64Volume4,319 shsAverage Volume460,271 shsMarket Capitalization$95.58 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Checkpoint Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,196.7% Upside$24.00 Price TargetShort InterestHealthy3.57% of Shares Sold ShortDividend StrengthN/ASustainability-0.63Upright™ Environmental ScoreNews Sentiment-0.35Based on 8 Articles This WeekInsider TradingSelling Shares$320,160 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.70) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.89 out of 5 starsMedical Sector620th out of 1,428 stocksPharmaceutical Preparations Industry302nd out of 680 stocks 3.5 Analyst's Opinion Consensus RatingCheckpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Checkpoint Therapeutics has a forecasted upside of 2,196.7% from its current price of $1.05.Amount of Analyst CoverageCheckpoint Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.57% of the outstanding shares of Checkpoint Therapeutics have been sold short.Short Interest Ratio / Days to CoverCheckpoint Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Checkpoint Therapeutics has recently decreased by 4.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCheckpoint Therapeutics does not currently pay a dividend.Dividend GrowthCheckpoint Therapeutics does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCheckpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Checkpoint Therapeutics is -0.63. Previous Next 2.0 News and Social Media Coverage News SentimentCheckpoint Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Checkpoint Therapeutics this week, compared to 1 article on an average week.Search Interest10 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $320,160.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Checkpoint Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.87% of the stock of Checkpoint Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Checkpoint Therapeutics are expected to decrease in the coming year, from ($0.70) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Checkpoint Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Checkpoint Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCheckpoint Therapeutics has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CKPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Checkpoint Therapeutics (NASDAQ:CKPT) StockCheckpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Read More CKPT Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 15,000 SharesJuly 2, 2022 | americanbankingnews.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 21,000 SharesJuly 2, 2022 | americanbankingnews.comCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 228,000 SharesJune 30, 2022 | finance.yahoo.comWe're Keeping An Eye On Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn RateJune 17, 2022 | markets.businessinsider.comCheckpoint set to present its latest technologies at NRF Protect 2022June 16, 2022 | msn.comCheckpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer PatientsJune 16, 2022 | seekingalpha.comCheckpoint Therapeutics trial generates positive interim results for skin cancer candidateJune 16, 2022 | nasdaq.comCheckpoint Reports Positive Interim Efficacy Results From Trial Evaluating CosibelimabJune 16, 2022 | marketwatch.comCheckpoint Therapeutics Shares Rise Premarket on Positive Study >CKPTMay 14, 2022 | seekingalpha.comCheckpoint Therapeutics GAAP EPS of -$0.20May 13, 2022 | seekingalpha.comCheckpoint gains as H.C. Wainwright cheers key regulatory milestone in EuropeMay 13, 2022 | finance.yahoo.comCheckpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsMay 4, 2022 | msn.comNovato PD To Hold DUI CheckpointMay 4, 2022 | msn.comAll Stormtrooper Checkpoint locations in FortniteApril 27, 2022 | msn.comDUI Checkpoint Scheduled This Weekend In WildomarMarch 31, 2022 | finance.yahoo.comHere's What Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shareholder Ownership Structure Looks LikeMarch 29, 2022 | benzinga.comCheckpoint Therapeutics's Return On Capital Employed InsightsMarch 28, 2022 | finance.yahoo.comCheckpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsMarch 18, 2022 | apnews.comGlobal Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight to 2028 - ResearchAndMarkets.comMarch 10, 2022 | finance.yahoo.com2 “Strong Buy” Penny Stocks With Over 300% Upside PotentialFebruary 15, 2022 | msn.comDUI Checkpoint Scheduled In Lake ElsinoreJanuary 25, 2022 | finance.yahoo.comCheckpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology ConferenceJanuary 25, 2022 | msn.comPeering Into Checkpoint Therapeutics Inc's Recent Short InterestJanuary 25, 2022 | seekingalpha.comCheckpoint Therapeutics jumps after trial win; Analysts boost price targetJanuary 25, 2022 | msn.com(CKPT) - Analyzing Checkpoint Therapeutics Inc's Short InterestSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CKPT CUSIPN/A CIK1651407 Webwww.checkpointtx.com Phone(781) 652-4500FaxN/AEmployees14Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$26.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+1,804.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,670,000.00 Net Margins-26,592.46% Pretax Margin-26,592.46% Return on Equity-173.15% Return on Assets-118.75% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$270,000.00 Price / Sales354.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book3.09Miscellaneous Outstanding Shares91,030,000Free Float85,473,000Market Cap$95.58 million OptionableNot Optionable Beta1.77 Checkpoint Therapeutics Frequently Asked Questions Should I buy or sell Checkpoint Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Checkpoint Therapeutics stock. View analyst ratings for Checkpoint Therapeutics or view top-rated stocks. What is Checkpoint Therapeutics' stock price forecast for 2022? 1 Wall Street research analysts have issued 12-month price objectives for Checkpoint Therapeutics' stock. Their CKPT stock forecasts range from $20.00 to $26.00. On average, they predict Checkpoint Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 2,185.7% from the stock's current price. View analysts' price targets for Checkpoint Therapeutics or view top-rated stocks among Wall Street analysts. How has Checkpoint Therapeutics' stock price performed in 2022? Checkpoint Therapeutics' stock was trading at $3.11 at the beginning of 2022. Since then, CKPT stock has decreased by 66.2% and is now trading at $1.05. View the best growth stocks for 2022 here. When is Checkpoint Therapeutics' next earnings date? Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Checkpoint Therapeutics. How were Checkpoint Therapeutics' earnings last quarter? Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) issued its earnings results on Thursday, May, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.09. The business earned $0.05 million during the quarter, compared to analysts' expectations of $0.07 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 173.15% and a negative net margin of 26,592.46%. View Checkpoint Therapeutics' earnings history. Who are Checkpoint Therapeutics' key executives? Checkpoint Therapeutics' management team includes the following people: Mr. James F. Oliviero III, C.F.A., CFA, Pres, CEO & Director (Age 46, Pay $874.8k)Mr. William Garrett Gray, CFO, Corp. Sec. & Treasurer (Age 35, Pay $350.94k) (LinkedIn Profile) Who are some of Checkpoint Therapeutics' key competitors? Some companies that are related to Checkpoint Therapeutics include Aerovate Therapeutics (AVTE), Phathom Pharmaceuticals (PHAT), Vera Therapeutics (VERA), Affimed (AFMD), Akero Therapeutics (AKRO), ALX Oncology (ALXO), Clovis Oncology (CLVS), Tyra Biosciences (TYRA), Gracell Biotechnologies (GRCL), Khosla Ventures Acquisition (KVSA), Seres Therapeutics (MCRB), Zymeworks (ZYME), Silence Therapeutics (SLN), Precigen (PGEN) and DiaMedica Therapeutics (DMCAF). View all of CKPT's competitors. What other stocks do shareholders of Checkpoint Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL). What is Checkpoint Therapeutics' stock symbol? Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT." How do I buy shares of Checkpoint Therapeutics? Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Checkpoint Therapeutics' stock price today? One share of CKPT stock can currently be purchased for approximately $1.05. How much money does Checkpoint Therapeutics make? Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $95.58 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. How many employees does Checkpoint Therapeutics have? Checkpoint Therapeutics employs 14 workers across the globe. How can I contact Checkpoint Therapeutics? Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for Checkpoint Therapeutics is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com. This page (NASDAQ:CKPT) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
